Notificação de acontecimentos adversos ou reclamações de qualidade
AZ Medical Global

Áreas Terapêuticas
Medicamentos
Recursos
Conectar

Login

Search Medical Information

Para pesquisar informação científica, deverá especificar pelo menos dois termos de pesquisa

Search Medical Information

American Society of Hematology (ASH) 2024

December 7 - 10, 2024

Acalabrutinib
AZD0486
Durvalumab; acalabrutinib
Oncology Unbranded

pdf

Acalabrutinib and rituximab in elderly patients with newly diagnosed mantle cell lymphoma including a matched population-based external comparator- the nordic lymphoma group NLG-MCL8 (ALTAMIRA) phase II trial

pdf

Fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia: Interim analysis of the multicenter, open-label, randomized, phase 3 AMPLIFY trial

pdf

Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

pdf

MRD-driven time-limited therapy of acalabrutinib and lenalidomide plus rituximab (ALR) or obinutuzumab (ALO) in patients with treatment-naïve mantle cell lymphoma: Phase 2 trial outcomes with MRD and cfDNA analyses

pdf

Primary endpoint evaluation of a multicenter, phase 2 study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a population of previously untreated patients with CLL enriched for high-risk disease

pdf

Real-world Bleeding Risk, Outcomes and Treatment Patterns of Patients with CLL/SLL Receiving BTKi with or without Prescription Anticoagulants or Antiplatelets

pdf

Acalabrutinib Versus Chlorambucil Plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia: A Randomized, Multicenter, Open-Label, Phase 3 Study (ChangE)

pdf

High-risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma

pdf

Treatment-Emergent Cardiovascular Events Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Treated with Bruton's Tyrosine Kinase Inhibitors (BTKi)

pdf

Efficacy and safety of Acalabrutinib treatment in very old (≥80y) and/or frail patients with Chronic Lymphocytic Leukemia (CLL) – Primary endpoint analysis of the phase II CLL-Frail Trial

pdf

Early Obinutuzumab significantly increases bone marrow undetectable MRD (10-4 sensitivity) (uMRD4) rate when combined with Acalabrutinib and Venetoclax in a randomized phase II trial for treatment naïve CLL

pdf

Acalabrutinib with Rituximab is highly effective first line treatment for elderly patients with mantle cell lymphoma

pdf

Preliminary efficacy and eafety of a phase I/II study of Acalabrutinib, Venetoclax, and Obinutuzumab in patients with relapsed/refractory and previously untreated mantle cell lymphoma (MAVO)

HTML

Acalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: 24-month efficacy and safety results from an open-label, multicenter phase 1/2 trial

html

Validation and implementation of flow cytometry based minimal residual disease (MRD) assay for chronic lymphocytic leukemia (CLL) clinical studies

HTML

A real-world comparative analysis of hypertension (HTN) and time to treatment failure (TTF) with acalabrutinib vs ibrutinib in treatment-naïve patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

html

Baseline characteristics from ARISE study, an Italian non-interventional study assessing the real-world use of Acalabrutinib in the treatment of patients with Chronic Lymphocytic Leukemia (CLL)

html

Real-world effectiveness and safety outcomes of acalabrutinib treatment in patients with relapsed/refractory mantle cell lymphoma

pdf

Evaluation of AZD0486, a novel CD19xCD3 T-Cell engager, in relapsed/refractory diffuse large B-cell lymphoma in an ongoing first-in-human phase 1 study: High complete responses seen in CAR-T–naive and CAR-T–exposed patients

pdf

Escalating Doses of AZD0486, a Novel CD19xCD3 T-cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma

pdf

Phase I study with dose expansion of acalabrutinib and durvalumab in primary central nervous system lymphoma

pdf

Pre-clinical Efficacy and Safety of AZD5492: a CD8-guided T Cell Engager for B-Non-Hodgkin Lymphoma Indications

pdf

A phase I study of dual targeting BCMA and CD19 FasTCAR-T cells (GC012F) as first-line therapy for transplant-ineligible newly diagnosed multiple myeloma

html

Brazilian reality of diffuse large B-Cell lymphoma (BRA – DLBCL): A multicenter retrospective study

html

Development of a high-throughput multiplex immunofluorescence pipeline in Classic Hodgkin Lymphoma whole slide formalin-fixed paraffin-embedded tissue samples

html

Practical considerations in correspondence to emerging regulatory feedback on dose escalation in early hematology clinical development

Não encontra o que procura?

Contacte-nos

Encontre um Medical Healthcare Partner

Submeter uma questão

A informação incluída neste website é dirigida exclusivamente a profissionais de saúde.

©2024 AstraZeneca. Todos os direitos reservados. PT-19636

Aprovado a 12/2024.

Sobre o AZMedical

AstraZeneca Portugal

Inquérito de Satisfação

Política de Privacidade

Aviso Legal e Termos de Utilização

Notificação de acontecimentos adversos ou reclamações de qualidade

Política de Privacidade

Aviso Legal e Termos de Utilização